pharmaphorum

OCTOBER 26, 2022

The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period.

Recruitment 96

Recruitment Prospecting Marketing Patients 96

pharmaphorum

SEPTEMBER 11, 2022

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu , and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen’s $2.3 It had been approved since 2014 for moderate to severe cases only. billion oral psoriasis therapy Otezla (apremilast).

FDA 52

FDA Marketing Sales Patients 52

pharmaphorum

DECEMBER 29, 2022

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.

Retail 52

Retail Marketing Doctors Government 52

Legacy MEDSearch

JUNE 15, 2023

Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.

Patients 98

Patients Recruitment Pharmacology Side effects 98

Pharmaceutical Technology

JULY 8, 2022

In December 2014, Amgen’s landmark FDA approval saw Blincyto (blinatumomab) approved for relapsed/refractory (R/R) B-cell progenitor acute lymphoblastic leukaemia (B-ALL), at the time being the only marketed BiTE. Currently, there are 110 BiTEs in oncology clinical trials, with seven in Phase III and three in pre-registration.

Safety 59

Safety Sales Marketing Patients 59

pharmaphorum

AUGUST 19, 2022

Takeda’s drug has been widely tipped to become the dominant option for HAE attack prevention and make blockbuster sales, and is on course to achieve that, with sales in the three months ended 30 June this year approaching $250 million. It is administered as an intravenous injection.

Sales 52

Sales Pharma Patients Medicine 52

pharmaphorum

SEPTEMBER 27, 2022

The suit claimed that Biogen paid millions of dollars to doctors in the form of speaker honoraria, training fees, consulting fees, and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014.

Government 44

Government Doctors Consulting Training 44

Pharmaceutical Technology

OCTOBER 5, 2022

Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). Ferry describes a popular solution among pharmaceutical companies.

Government 59

Government Specialization Physicians Education 59

Legacy MEDSearch

JUNE 27, 2022

This funding will help propel the company into new surgical applications, accelerate its commercial sales and add to its growing clinical evidence repository. IOPS® is FDA 510(k) cleared and currently launching in the US at select sites. Founded in 2014, Centerline Biomedical is headquartered in Cleveland, Ohio.

Recruitment 52

Recruitment Healthcare Healthcare Safety 52

pharmaphorum

DECEMBER 14, 2022

Researchers cautioned that these are early results, and more follow-up is needed to determine the long-term safety and efficacy, but the data could spell trouble for AZ and Alexion’s C5 franchise, which brought in more than $4 billion in sales in the first nine months of this year.

Side effects 52

Side effects Patients Sales Safety 52

Pharmaceutical Technology

FEBRUARY 22, 2023

Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US. Amgen sued the two companies in 2014 over supposed patent infringement. Amgen’s Repatha was greenlit a month later.

Pharma 104

Pharma Government FDA Sales 104

European Pharmaceutical Review

AUGUST 23, 2022

On- or in-dose authentication means that a security measure or anticounterfeit feature is integrated with the dosage form itself, offering product verification and traceability embedded into each medicine, rather than on the secondary package” WHO estimates that >50 percent of the drugs for sale on the internet are fake.

Medicine 89

Medicine Food and Drug Administration Pharmaceutical products Pharmaceutical 89

Evolve Your Success

JANUARY 23, 2024

In the changing balance between innovation and tradition, medical sales succeeds with personal connection, persistence, and the commitment to link technology and patient care. For today’s episode, we have Edouard Saget to discuss the big question: Will AI replace medical sales workforce and surgeons? Tune in to find out!

Medical sales 52

Medical sales Medical Sales Physicians 52

European Pharmaceutical Review

JUNE 8, 2023

1 In the EU, the Tobacco Products Directive (2014/40/EU) governs “the manufacture, presentation and sale of tobacco and related products”. 1 In the EU, the Tobacco Products Directive (2014/40/EU) governs “the manufacture, presentation and sale of tobacco and related products”. The AIs for NNN and NNK are 96.0

Food and Drug Administration 59

Food and Drug Administration FDA Manufacturing Law & Regulation 59

Legacy MEDSearch

FEBRUARY 10, 2023

Food and Drug Administration (FDA) to market its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head. Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., Catalyst OrthoScience Inc. About Catalyst OrthoScience Inc. Headquartered in Naples, Fla., Are you hiring?

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Rituximab biosimilars have since achieved notable commercial success, with global sales surpassing $900m collectively.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

MARCH 30, 2023

Broadening uses and secured full approvals Since its first approval in September 2014, Keytruda has achieved blockbuster status on the market. In 2022, the company reported Keytuda sales of $20.9 In 2022, the company reported Keytuda sales of $20.9 billion in its FY 2022 results. billion in its FY 2022 results. billion in 2028.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Top companies and drugs by sales in 2021. He has been a key member of the executive team, most recently serving as the company’s Vice President, Strategy since 2014. References Urquhart L. 2022;21(4):251–.

Food and Drug Administration 86

Food and Drug Administration Manufacturing Safety Pharmaceutical 86

Legacy MEDSearch

OCTOBER 6, 2022

” Founded in 2014 with the vision of saving lives through the democratization of innovative medical technologies, Body Vision Medical’s first commercial product, LungVision , uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans. About Body Vision Medical.

Consulting 52

Consulting Medical Recruitment Marketing 52

Pharmaceutical Technology

JUNE 21, 2023

This is the first time the FDA has approved an oral diabetes drug for paediatric patients since its approval of metformin in 2000. The FDA first approved Jardiance to help control blood sugar in adults with T2D in 2014. from Jardiance’s sales in 2022 while Boehringer Ingelheim made Synjardy sales amounting to €5.83bn ($6.37bn).

Medicine 59

Medicine FDA Food and Drug Administration Sales 59

Pharmaceutical Technology

JANUARY 6, 2023

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. These actions allegedly led to the extension of Novartis’ patents.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97

Pharmaceutical Technology

MAY 26, 2023

The FDA has flagged this issue as pharmacies selling prescription drugs illegally have proliferated over the years. The US Food and Drug Administration (FDA commissioner Dr. Robert Califf says, “The illegal sale of prescription drug stimulants online puts Americans at risk and contributes to potential abuse, misuse, and overdose.”

Food and Drug Administration 52

Food and Drug Administration Prescription FDA Medical 52

Legacy MEDSearch

AUGUST 11, 2022

OSSIOfiber Suture Anchors were FDA cleared in March 2022 for use in “fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee, hand/wrist, and elbow” in a variety of specific orthopedic procedures. This is another big step for OSSIOfiber in becoming a new material standard in orthopedic fixation.”. About OSSIO.

Recruitment 52

Recruitment Marketing Safety Medical 52

Pharmaceutical Technology

APRIL 20, 2023

In 2022, Otezla made up for 9% of Amgen’s total product sales, having sold over $2.2 Since the lawsuit began, the FDA has approved Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib), another small molecule for psoriasis treatment. The FDA first approved Otezla in March 2014 for the treatment of psoriatic arthritis.

Competition 52

Competition Marketing FDA Prospecting 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Anti-obesity therapeutic landscape. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Anti-obesity therapeutic landscape. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98